Result was below consensus.
Goldman have EPS of 34c in FY23 and 24c in FY24.
"the key debate with the stock is the underlying (ex-Covid) profitability". GS think management are executing well.
Not a holder but considering it.
- Forums
- ASX - By Stock
- ACL
- Ann: Second letter from Crescent Capital
ACL
australian clinical labs limited
Add to My Watchlist
1.41%
!
$2.79

Ann: Second letter from Crescent Capital, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.79 |
Change
-0.040(1.41%) |
Mkt cap ! $548.9M |
Open | High | Low | Value | Volume |
$2.83 | $2.83 | $2.78 | $937.4K | 335.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 5554 | $2.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.80 | 10833 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 6566 | 2.790 |
16 | 93146 | 2.780 |
13 | 67243 | 2.770 |
11 | 44445 | 2.760 |
12 | 15318 | 2.750 |
Price($) | Vol. | No. |
---|---|---|
2.800 | 10762 | 21 |
2.810 | 13058 | 15 |
2.820 | 17751 | 10 |
2.830 | 27283 | 8 |
2.840 | 10783 | 3 |
Last trade - 13.22pm 29/07/2025 (20 minute delay) ? |
Featured News
ACL (ASX) Chart |